HSF2 and neoplasm: Among them, only the TCR targeting H2-Db-restricted Hsf2 p.K72N (‘p’ indicating peptide residue) confers specific recognition of the B16F10 cells in vitro and demonstrates anti-tumour effect in vivo, albeit dependent upon sufficient tumour expression of neoAg Hsf2 p.K72N.